Oral tirzepatide or orforglipron: comparing two weight-loss pills

Two very different kinds of pill

Orforglipron is a small-molecule drug designed from the start to be swallowed. It activates the GLP-1 receptor, the same target as semaglutide, but it is not a peptide, so stomach acid and enzymes do not break it down the way they do protein-based drugs. That is why it can be taken at any time of day, with or without food.

Tirzepatide is a peptide that activates both GIP and GLP-1 receptors. Its FDA-approved forms, Zepbound and Mounjaro, are weekly injections, and the Zepbound label lists subcutaneous use only. Oral tirzepatide capsules are made by compounding pharmacies, which choose their own formulation and absorption aids.

What the orforglipron trial showed

Orforglipron's approval rested largely on the 72-week ATTAIN-1 trial in adults with obesity or overweight. As reported by Healio, average weight loss in those who stayed on treatment was 7.8%, 9.3% and 12.4% at the three doses tested. Blood pressure and several cholesterol measures also improved.

The most common side effects were mild to moderate gastrointestinal effects such as nausea, typical of the GLP-1 class. Doses are started low and raised in steps of at least 30 days.

What is known about oral tirzepatide

Injectable tirzepatide has extensive trial evidence for weight management and for obstructive sleep apnea in adults with obesity. None of that evidence comes from capsules. No published trial has measured how much tirzepatide a compounded capsule delivers, how consistent that is from batch to batch or what weight loss it produces.

So while tirzepatide is a powerful molecule when injected, it is not accurate to assume a capsule matches the injection. It may work less well, and individual response is hard to predict. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality. As of May 31, 2026, the FDA had received more than 730 adverse event reports involving compounded tirzepatide in all forms.

Side by side

• FDA status: orforglipron approved; oral tirzepatide not approved in any form.
• Molecule: orforglipron is a small molecule acting on GLP-1; tirzepatide is a peptide acting on GIP and GLP-1.
• Evidence: orforglipron has large randomized trials; compounded oral tirzepatide has none.
• Taking it: orforglipron once daily without food or water rules; capsule instructions come from your prescriber and pharmacy.
• Predictability: orforglipron's effect is characterized in trials; capsule absorption is unknown and may vary.
• Insurance: orforglipron coverage varies by plan; compounded capsules are generally not covered.

Cautions shared by both

Both drugs act on the GLP-1 pathway, so similar side effects apply: nausea, vomiting, diarrhea and constipation, and a need to watch for dehydration, pancreatitis and gallbladder problems. Tirzepatide carries a boxed warning about thyroid C-cell tumors in rats and is not used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Ask your clinician about the specific warnings on the Foundayo label.

Neither should be used in pregnancy. Never take two GLP-1 or tirzepatide products together; the Zepbound label specifically advises against combining them. Tirzepatide can also reduce the reliability of birth control pills, so a backup method is advised after starting and after dose increases.

Questions to ask before you decide

• How important is avoiding injections to me compared with getting the most predictable result?
• Can I realistically follow a daily pill routine, or would a weekly injection be easier?
• Do I have coverage that changes the cost of an approved option?
• What will tell us, and by when, that a compounded capsule is not working well enough?
• Do I take thyroid medicine, birth control pills or other drugs whose absorption could be affected?
• Is there any personal or family history of medullary thyroid cancer, pancreatitis or gallbladder disease?

How to think about the choice

If you want a pill with a predictable, trial-tested effect and no morning ritual, orforglipron is the stronger evidence-based option, and your clinician can discuss cost and coverage. If you are open to injections and want the largest expected effect, injectable tirzepatide, branded or compounded, is worth discussing.

Compounded oral tirzepatide can be considered for an informed patient who understands the evidence gap and is willing to be monitored closely. Through HealifyMD it is $399/month, confirmed at the eligibility review, with no membership fee and labs priced separately. If you obtain a branded GLP-1 through your own coverage, our weight loss membership is from $75/month.